Status:
UNKNOWN
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
Liver cancer is one of the most common malignant tumors worldwide with high morbidity and mortality, and hepatocellular carcinoma (HCC) is the main histological subtype. So far, liver resection is the...
Detailed Description
MVI and MRD confirmed by postoperative pathology are important prognostic factors for recurrence after liver resection, but current assessment methods have low sensitivity and specificity. cfDNA refer...
Eligibility Criteria
Inclusion
- 18 to 80 years old;
- clinical diagnosis of liver cancer;
- intend to perform surgical treatment;
- postoperative pathological diagnosis of hepatocellular carcinoma;
- signed informed consent.
Exclusion
- Not diagnosed with liver mass;
- Not undergo liver resection;
- Postoperative pathological diagnosis of non-hepatocellular carcinoma;
- Under the age of 18 or over 80;
- Concomitant pregnancy;
- Concomitant serious complications, including end-stage lung disease, unstable coronary heart disease or congestive heart failure grade 3-4, chronic kidney disease stage 4-5, cirrhosis (Child-Pugh) grade C, immunodeficiency;
- Incomplete data records.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05371873
Start Date
March 1 2021
End Date
March 1 2025
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital，College of Medicine，Zhejiang University
Hangzhou, Zhejiang, China, 310003